Immunome, Inc. (IMNM) vs Novavax, Inc. (NVAX)
A side-by-side comparison of Immunome, Inc. and Novavax, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IMNM
Immunome, Inc.
$19.37HealthcareDelayed quote: Oct 6, 2026, 2:00 PM EDT
NVAX
Novavax, Inc.
$10.94HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — IMNM vs NVAX
growth of $100 · dividends reinvested · last 6yIMNM +57.4% (+7.9%/yr)NVAX -87.7% (-29.5%/yr)IMNM compounded faster over this window
Log scale — wide-divergence pair
IMNM NVAX
IMNM vs NVAX: by the numbers
- •IMNM is the larger company ($1.85B vs $1.80B market cap).
- •Both run net losses; NVAX's is the smaller (-59.87% vs -3059.99% net margin).
Metrics side by side
Valuation
| Metric | IMNM | NVAX |
|---|---|---|
| P/S ratio | N/A | 4.35 |
| P/B ratio | 3.53 | N/A |
Profitability
| Metric | IMNM | NVAX |
|---|---|---|
| Gross margin | 57.43% | 93.67% |
| Operating margin | -3084.76% | 50.14% |
| Net margin | -3059.99% | -59.87% |
| ROE | -48.43% | N/A |
| ROIC | -51.06% | -36.37% |
Growth (annualized)
| Metric | IMNM | NVAX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 118.86% |
| Total return CAGR (5Y) | 2.88% | -40.61% |
Frequently asked
- How have IMNM and NVAX total returns compared?
- Over the past 5 years, IMNM delivered 2.88% and NVAX delivered -40.61% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Immunome ROENovavax ROEImmunome operating marginNovavax operating marginImmunome revenue growthNovavax revenue growthImmunome free cash flowNovavax free cash flow
Immunome & Novavax appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.